Suven Pharmaceuticals Ltd Analyst Rating
based on 1 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 1 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹1435
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Share analysis
Suven Pharmaceuticals Ltd price forecast by 1 analysts
Upside of27.84%
High
₹1435
Target
₹1435.00
Low
₹1435
Suven Pharmaceuticals Ltd target price ₹1435, a slight upside of 27.84% compared to current price of ₹1114.45. According to 1 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Suven Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2024:3.65%
Forecast
Actual
Including amortisation and stock based compensations
Suven Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2024:11.44%
Forecast
Actual
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,089Day's Price Range₹1,128.752 Week's Low
52 Week's High
₹585.252-Week Price Range₹1,360
| Returns % | |
| 1 Month Return | -14.25 % |
| 3 Month Return | -6.01 % |
| 1 Year Return | + 54.28 % |
| Market Stats | |
| Previous Close | ₹1,122.50 |
| Open | ₹1,103.30 |
| Volume | 5.96L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹28,574.92Cr |
Suven Pharmaceuticals Ltd Key Statistics
| P/E Ratio | 117.42 |
| PEG Ratio | -15.85 |
| Market Cap | ₹28,574.92 Cr |
| P/B Ratio | 8.38 |
| EPS | 11.8 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 14.31 |
Suven Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹28,574.92 Cr | 113.21% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹17,202.81 Cr | 26.5% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,512.82 Cr | 5.02% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹15,787.22 Cr | 49.06% | 0.68 | ₹218 Cr | ₹1,296 Cr | |
| BUY | ₹27,154.28 Cr | 231.1% | 0.55 | ₹258 Cr | ₹1,375 Cr |
About Suven Pharmaceuticals Ltd
Share Price: ₹1114.45 per share as on 02 Jan, 2025 04:02 PM
Market Capitalisation: ₹28,574.92Cr as of today
Revenue: ₹257.72Cr as on September 2024 (Q3 24)
Net Profit: ₹81.98Cr as on September 2024 (Q3 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
| Organisation | Suven Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Stock Surges Amid Positive Performance - 31 Dec, 2024
On December 31, 2024, Suven Pharmaceuticals shares increased by 5%, reaching Rs 1,141.5. The stock has gained 63.7% over the past year, despite a recent quarterly profit decline.Suven Pharmaceuticals Stock Declines Amid Market Fluctuations - 30 Dec, 2024
On December 30, 2024, Suven Pharmaceuticals stock fell by 3.84%, underperforming its sector. The stock reached an intraday low of Rs 1128.8 and has declined 13.20% over the past month. Currently rated as a Hold by MarketsMOJO, the stock is above its 200-day moving average but below shorter-term averages.Suven Pharmaceuticals Acquires Majority Stake in NJ Bio - 23 Dec, 2024
Suven Pharmaceuticals has successfully completed the acquisition of a 56% equity stake in NJ Bio, Inc. for $64.4 million. This strategic move aims to strengthen its market position and leverage innovative technologies for sustainable growth.Suven Pharmaceuticals Serves Diverse Customer Base - 20 Dec, 2024
Suven Pharmaceuticals has 443 customers across various sectors, including pharmaceuticals and chemicals. Notably, they serve 30 of the 80 pharmaceutical and chemical companies in the NSE 500 index as of June 30, 2024.Suven Pharmaceuticals Acquires Stake in NJ Bio - 09 Dec, 2024
Suven Pharmaceuticals has signed definitive agreements to acquire a 56% controlling stake in NJ Bio, Inc. for $64.4 million, enhancing its position in the antibody-drug conjugates market.Suven Pharma Acquires Majority Stake in NJ Bio - 07 Dec, 2024
Suven Pharmaceuticals has acquired a 56% controlling stake in NJ Bio Inc. for $64.4 million, strengthening its presence in the rapidly growing ADC market, projected to grow over 25% annually. The acquisition will enhance Suven's capabilities and market reach in the U.S. and is expected to close by the end of December 2024.Suven Pharma Recognized for Sustainable Growth - 04 Dec, 2024
Suven Pharmaceuticals has been ranked among the global top 20 companies for sustainable growth in the drugs industry by TIME and Statista. The recognition highlights the company's achievements in revenue growth, profitability, and sustainability practices, including reduced carbon footprint and increased green energy usage.Suven Pharmaceuticals Ltd Gains 4.23% Today - 02 Dec, 2024
Suven Pharmaceuticals Ltd surged 4.23% to Rs 1359, outperforming the BSE Healthcare index, which fell 0.46% over the past month. The stock has increased 2.28% in the last month, while the BSE Healthcare index is up 44.02% year-over-year.
Insights on Suven Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 9.80% to 10.70% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 248.85 Cr → 271.84 Cr (in ₹), with an average increase of 8.5% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 46.75 Cr → 82.21 Cr (in ₹), with an average increase of 16.9% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 50.10% of holdings in Sep 2024 quarter
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 14.78% to 14.12% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 22.67% to 22.25% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, SUVENPHAR stock has moved down by -14.3%
Suven Pharmaceuticals Ltd Financials
Index Inclusions
Suven Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.1% | 0.00 | |
| Foreign Institutions | 10.7% | 9.15 | |
| Mutual Funds | 14.12% | ||
| Retail Investors | 22.25% | ||
| Others | 2.84% | 6.91 |
Suven Pharmaceuticals Ltd Key Indicators
Suven Pharmaceuticals Ltd Valuation
Suven Pharmaceuticals Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (58.41x)
January 1, 2025
Today (117.42x)
January 1, 2025
Highest (139.56x)
November 5, 2024
Suven Pharmaceuticals Ltd Earnings and Dividends
Suven Pharmaceuticals Ltd Earnings Results
Suven Pharmaceuticals Ltd’s net profit jumped 3.33% since last year same period to ₹82.21Cr in the Q2 2024-2025. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 35.28% jump in its net profits since last 3-months.
Read More about Earnings ResultsSuven Pharmaceuticals Ltd Dividends September,2022
In the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 0.98%.
Read More about Dividends
Suven Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Suven Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Suven Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Suven Pharmaceuticals Ltd shares.
Suven Pharmaceuticals Ltd (SUVENPHAR) share price today is ₹1114.45
Suven Pharmaceuticals Ltd is listed on NSE
Suven Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Suven Pharmaceuticals Ltd is ₹1128.7.
- Today’s lowest price of Suven Pharmaceuticals Ltd is ₹1089.
PE Ratio of Suven Pharmaceuticals Ltd is 117.42
PE ratio = Suven Pharmaceuticals Ltd Market price per share / Suven Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 5.96L.
Today’s market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹28574.92Cr.
| Suven Pharmaceuticals Ltd(SUVENPHAR | Price |
|---|---|
52 Week High | ₹1360 |
52 Week Low | ₹585.2 |
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1114.45. It is down -18.06% from its 52 Week High price of ₹1360
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1114.45. It is up 90.44% from its 52 Week Low price of ₹585.2
| Suven Pharmaceuticals Ltd(SUVENPHAR | Returns |
|---|---|
1 Day Returns | -8.05% |
1 Month Returns | -14.25% |
3 Month Returns | -6.01% |
1 Year Returns | 54.28% |